The Institutional Review Board approved the activation of six new protocols in 2008. There are currently 22 active protocols.

These new protocols were approved in 2008:

NCCTG N0572
Phase I/II Trial of Sorafenib and CCI-779 in Patients with Recurrent Glioblastoma

NCCTG N063D/BIG 2-06, ALTTO
Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Study

NCCTG N06CA
The Use of Topical Baclofen, Amitriptyline HCL, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study

NCCTG N05C7
Long Acting Methylphenidate (ConcertaTM) for Cancer-Related Fatigue: A Phase III Randomized, Double-Blind Placebo Controlled Study

CALGB-40503
Endocrine Therapy in combination with Anti-VEGF Therapy: A Randomized, Double-Blind, Placebo Controlled Phase III Trial of Endocrine Therapy Alone or Endocrine therapy Plus Bevacizumab for Women with Hormone Receptor-positive Advanced Breast Cancer

NCCTG-N0723
MARVEL: Marker Validation of Erlotinib in Lung Cancer

There were four new patients randomized to various trials in 2008. In addition to those patients currently receiving therapy, follow up information continues to be collected on an additional 25 patients.

Rice Memorial Hospital participates in the oncology clinical trials program through affiliation with the North Central Cancer Treatment Group as an affiliate of Mayo Clinic, and the national Clinical Trials Support Unit, all of which are sponsored by the National Cancer Institute.

Marci Haraldson, RN, BA, OCN
Oncology Research